Proteomics analyses of human plasma reveal triosephosphate isomerase as a potential blood marker of methotrexate resistance in rheumatoid arthritis
Authors' conclusion
A first step was achieved in the search for biomarkers of MTXR, with the identification of two actors in glycolysis (TPI-1 and GPI).
Study context
- Population
- RA patients treated with a stable dose of s.c. MTX for at least 3 months
- Participants
- 32 vs 24
- Exposure
- Active RA vs RA in remission after MTX treatment
- Active diseasen = 32
- Remissionn = 24reference
- Outcome
- Differentially expressed plasma proteins between active RA and remission (biomarker of MTX resistance)
Methodological detailsuntargeted proteomics analysis, targeted proteomics confirmation, Groups homogeneous in epidemiological characteristics except longer treatment duration in the remission group
- Untargeted proteomics analysis
- Targeted proteomics confirmation
- Groups homogeneous in epidemiological characteristics except longer treatment duration in the remission group
Main finding
As reported in the abstract
Differentially expressed plasma proteins
- Untargeted proteomics: plasma proteins differentially expressed between the two groups
- 8
Observational data: associations, not effects.
Original publication
Proteomics analyses of human plasma reveal triosephosphate isomerase as a potential blood marker of methotrexate resistance in rheumatoid arthritis. Rheumatology (Oxford). Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →